News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,683 Results
Type
Article (43220)
Company Profile (307)
Press Release (686144)
Multimedia
Podcasts (102)
Webinars (17)
Section
Business (210738)
Career Advice (2107)
Deals (36689)
Drug Delivery (111)
Drug Development (83264)
Employer Resources (176)
FDA (16707)
Job Trends (15468)
News (356777)
Policy (34076)
Tag
Academia (2601)
Accelerated approval (14)
Adcomms (25)
Allergies (115)
Alliances (51585)
ALS (129)
Alzheimer's disease (1535)
Antibody-drug conjugate (ADC) (178)
Approvals (16756)
Artificial intelligence (372)
Autoimmune disease (41)
Automation (23)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (140)
Biotechnology (189)
Bladder cancer (111)
Brain cancer (43)
Breast cancer (413)
Cancer (3340)
Cardiovascular disease (280)
Career advice (1773)
Career pathing (33)
CAR-T (206)
CDC (40)
Cell therapy (552)
Cervical cancer (27)
Clinical research (69035)
Collaboration (1209)
Company closure (4)
Compensation (842)
Complete response letters (43)
COVID-19 (2738)
CRISPR (73)
C-suite (484)
Cystic fibrosis (124)
Data (3695)
Decentralized trials (2)
Denatured (32)
Depression (82)
Diabetes (391)
Diagnostics (6570)
Digital health (27)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (167)
Drug pricing (152)
Drug shortages (31)
Duchenne muscular dystrophy (172)
Earnings (90257)
Editorial (46)
Employer branding (22)
Employer resources (152)
Events (117523)
Executive appointments (910)
FDA (18868)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1056)
Gene editing (154)
Generative AI (27)
Gene therapy (447)
GLP-1 (883)
Government (4710)
Grass and pollen (6)
Guidances (331)
Healthcare (19038)
HIV (42)
Huntington's disease (32)
IgA nephropathy (49)
Immunology and inflammation (197)
Immuno-oncology (14)
Indications (46)
Infectious disease (2931)
Inflammatory bowel disease (166)
Inflation Reduction Act (10)
Influenza (77)
Intellectual property (159)
Interviews (327)
IPO (16882)
IRA (55)
Job creations (4071)
Job search strategy (1500)
Kidney cancer (13)
Labor market (63)
Layoffs (548)
Leadership (24)
Legal (8413)
Liver cancer (84)
Longevity (12)
Lung cancer (481)
Lymphoma (245)
Machine learning (22)
Management (59)
Manufacturing (527)
MASH (110)
Medical device (13643)
Medtech (13660)
Mergers & acquisitions (20608)
Metabolic disorders (974)
Multiple sclerosis (110)
NASH (17)
Neurodegenerative disease (157)
Neuropsychiatric disorders (40)
Neuroscience (2363)
NextGen: Class of 2025 (6645)
Non-profit (4541)
Now hiring (54)
Obesity (482)
Opinion (255)
Ovarian cancer (111)
Pain (151)
Pancreatic cancer (142)
Parkinson's disease (200)
Partnered (24)
Patents (369)
Patient recruitment (263)
Peanut (55)
People (60007)
Pharmaceutical (90)
Pharmacy benefit managers (23)
Phase I (21389)
Phase II (30382)
Phase III (22739)
Pipeline (2400)
Policy (247)
Postmarket research (2655)
Preclinical (9131)
Press Release (68)
Prostate cancer (162)
Psychedelics (41)
Radiopharmaceuticals (261)
Rare diseases (547)
Real estate (6278)
Recruiting (69)
Regulatory (24002)
Reports (51)
Research institute (2384)
Resumes & cover letters (360)
Rett syndrome (11)
RNA editing (12)
RSV (55)
Schizophrenia (114)
Series A (175)
Series B (131)
Service/supplier (12)
Sickle cell disease (72)
Special edition (21)
Spinal muscular atrophy (152)
Sponsored (35)
Startups (3747)
State (2)
Stomach cancer (15)
Supply chain (87)
Tariffs (81)
The Weekly (68)
Vaccines (893)
Venture capital (59)
Weight loss (312)
Women's health (51)
Worklife (17)
Date
Today (109)
Last 7 days (430)
Last 30 days (2264)
Last 365 days (31359)
2025 (21933)
2024 (35778)
2023 (40634)
2022 (51807)
2021 (56339)
2020 (54799)
2019 (47399)
2018 (35776)
2017 (33147)
2016 (32670)
2015 (38623)
2014 (32520)
2013 (27637)
2012 (29732)
2011 (30487)
2010 (28497)
Location
Africa (791)
Alabama (69)
Alaska (7)
Arizona (265)
Arkansas (14)
Asia (41370)
Australia (6612)
California (8572)
Canada (2653)
China (800)
Colorado (359)
Connecticut (364)
Delaware (227)
Europe (88542)
Florida (1280)
Georgia (285)
Hawaii (2)
Idaho (60)
Illinois (695)
India (40)
Indiana (411)
Iowa (17)
Japan (266)
Kansas (114)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1141)
Massachusetts (6316)
Michigan (266)
Minnesota (507)
Mississippi (4)
Missouri (101)
Montana (28)
Nebraska (25)
Nevada (98)
New Hampshire (68)
New Jersey (2347)
New Mexico (29)
New York (2330)
North Carolina (1211)
North Dakota (8)
Northern California (3874)
Ohio (262)
Oklahoma (17)
Oregon (40)
Pennsylvania (1813)
Puerto Rico (17)
Rhode Island (41)
South America (1167)
South Carolina (44)
South Dakota (1)
Southern California (3295)
Tennessee (138)
Texas (1322)
United States (31332)
Utah (255)
Virginia (222)
Washington D.C. (74)
Washington State (715)
West Virginia (4)
Wisconsin (74)
729,683 Results for "regeneron pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
Regeneron’s antibody duos significantly lowered eye itching and redness, as well as pin prick reactivity, in people with cat and birch allergies. Still, BMO Capital Markets expressed uncertainty about the assets’ “commercial potential in a highly generic market.”
September 9, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Two FDA Decisions for Regeneron’s Eylea HD Delayed Into Q4
The delays, first revealed in Regeneron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.
August 21, 2025
·
2 min read
·
Tristan Manalac
Earnings
Regulatory Roadblocks Blemish Regeneron’s Otherwise Strong Q2
Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO Leonard Schleifer told investors.
August 1, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win
Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities of daily living in patients with generalized myasthenia gravis.
August 27, 2025
·
2 min read
·
Tristan Manalac
Accelerated approval
Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity
While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing convenience and efficacy.
July 3, 2025
·
2 min read
·
Tristan Manalac
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.
June 2, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” according to a spokesperson for the pharma.
June 16, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
Regeneron promised to comply with 23andMe’s consumer privacy policies and related data security laws.
May 19, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Action Alert: Regeneron, Sanofi and Abeona
Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi.
April 14, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference - September 4, 2025
September 5, 2025
·
1 min read
1 of 72,969
Next
